ICON plc/$ICLR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Ticker
$ICLR
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Dublin, Ireland
Employees
41,250
ISIN
IE0005711209
Website
ICON plc Metrics
BasicAdvanced
$12B
15.98
$9.19
1.24
-
Price and volume
Market cap
$12B
Beta
1.24
52-week high
$342.55
52-week low
$125.10
Average daily volume
1.2M
Financial strength
Current ratio
1.27
Quick ratio
1.213
Long term debt to equity
37.142
Total debt to equity
37.455
Interest coverage (TTM)
5.59%
Profitability
EBITDA (TTM)
1,626.609
Gross margin (TTM)
29.08%
Net profit margin (TTM)
9.25%
Operating margin (TTM)
14.54%
Effective tax rate (TTM)
8.34%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
4.41%
Return on equity (TTM)
8.01%
Valuation
Price to earnings (TTM)
15.982
Price to revenue (TTM)
1.47
Price to book
1.23
Price to tangible book (TTM)
-3.81
Price to free cash flow (TTM)
11.381
Free cash flow yield (TTM)
8.79%
Free cash flow per share (TTM)
1,290.62%
Growth
Revenue change (TTM)
-0.48%
Earnings per share change (TTM)
11.53%
3-year revenue growth (CAGR)
7.89%
10-year revenue growth (CAGR)
18.18%
3-year earnings per share growth (CAGR)
60.21%
10-year earnings per share growth (CAGR)
11.63%
What the Analysts think about ICON plc
Analyst ratings (Buy, Hold, Sell) for ICON plc stock.
Bulls say / Bears say
ICON plc's full integration of Medidata Clinical Data Studio enhances data management and review processes, potentially improving operational efficiency and client satisfaction. (stocktitan.net)
The company's expansion of its artificial intelligence tools portfolio aims to deliver efficiencies across the clinical trial process, including study startup and resource forecasting, positioning ICON as a leader in innovative clinical research solutions. (iconplc.com)
ICON's appointment of a new Chief Operating Officer, Barry Balfe, in December 2024, is expected to strengthen its leadership team and drive strategic growth initiatives. (iconplc.com)
A 20% stock price decline in October 2024, following a significant revenue shortfall and reduced annual revenue guidance, has led to a securities fraud investigation, potentially impacting investor confidence. (globenewswire.com)
Analysts have flagged downside risks to ICON's growth projections, leading to a neutral stock rating, which may affect future stock performance. (investing.com)
The company's first-quarter 2025 revenue of $2 billion missed analyst expectations, indicating potential challenges in meeting market forecasts. (thetelegraph.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
ICON plc Financial Performance
Revenues and expenses
ICON plc Earnings Performance
Company profitability
ICON plc News
AllArticlesVideos
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
Business Wire·2 days ago
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
Business Wire·2 weeks ago
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ICON plc stock?
ICON plc (ICLR) has a market cap of $12B as of July 18, 2025.
What is the P/E ratio for ICON plc stock?
The price to earnings (P/E) ratio for ICON plc (ICLR) stock is 15.98 as of July 18, 2025.
Does ICON plc stock pay dividends?
No, ICON plc (ICLR) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next ICON plc dividend payment date?
ICON plc (ICLR) stock does not pay dividends to its shareholders.
What is the beta indicator for ICON plc?
ICON plc (ICLR) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.